Prognosis Implication of N-Terminal Pro-B-Type Natriuretic Peptide in Adult Patients With Acute Myocarditis

Figure 1. The flow chart of the enrollment of 170 adult patients with acute myocarditis from the overall population with acute myocarditis.

Figure 2. Receiver operating characteristic (ROC) curve of the ability of NT-proBNP and LVEF to predict 30-day death or heart transplantation (A) and long-term MACE (B) in patients with acute myocarditis. In predicting 30-day death or heart transplantation, the area under the curve (AUC) for NT-proBNP was 0.929, with 86.67% sensitivity and 89.68% specificity, while the AUC for LVEF was 0.843, with 86.67% sensitivity and 75.48% specificity. In predicting long-term MACE, the AUC for NT-proBNP was 0.733, with 62.07% sensitivity and 80.14% specificity, while the AUC for LVEF was 0.737, with 62.07% sensitivity and 87.23% specificity. MACE, major adverse cardiac events; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEF, left ventricular ventricle ejection fraction.

Figure 3. 30-day (A) and long-term (B) MACE-free survival among different quartiles of NT-proBNP in patients with acute myocarditis. Patients in the highest quartile of NT-proBNP had the most MACE in 30 days as well as in the long-term. Thirty day MACE included deaths and heart transplantation within 30 days after admission. Long-term MACE included deaths, heart transplantations, re-hospitalization for heart failure, and sustained ventricular arrhythmias (>30s).

Figure 4. Scatter figure showed a linear correlation between NT-proBNP levels and time of survival (days, Napierian Logarithm scale) in all patients who had long-term MACE (n = 29). MACE, major adverse cardiac events; NT-proBNP, N-terminal pro-B-type natriuretic peptide.